Novartis gene therapy approved, but will come at cost of more than $2 million

Babies born with a severe form of a rare genetic condition known as spinal muscular atrophy almost always die before their second birthday.

A gene therapy approved Friday by the Food and Drug Administration promises to change that, offering a potential one-time fix for the genetic deficiency behind the neuromuscular disease.